Pelthos Therapeutics Expands Pediatric Dermatology Portfolio with Xepi and Xeglyze Acquisitions

Company details path to public markets, early ZELSUVMI success, and plans to launch new impetigo and head lice treatments

Mar. 29, 2026 at 8:04am

Got story updates? Submit your updates here. ›

A high-end, photorealistic studio still-life photograph featuring three premium bottles and tubes representing Pelthos Therapeutics' pediatric dermatology products, arranged elegantly on a clean, monochromatic background and using dramatic lighting to convey the company's focus on innovative treatments.Pelthos Therapeutics expands its specialized dermatology product lineup to address common pediatric skin conditions.Durham Today

Pelthos Therapeutics executives discussed the company's journey to becoming a publicly traded entity, the early commercial performance of its lead product ZELSUVMI for molluscum contagiosum, and its plans to add two additional pediatric-focused dermatology treatments, Xepi for impetigo and Xeglyze for head lice, in an investor interview hosted by Roth Capital Partners.

Why it matters

Pelthos Therapeutics is expanding its portfolio of pediatric dermatology products, leveraging the success of its first FDA-approved treatment ZELSUVMI to drive growth. The additions of Xepi and Xeglyze allow the company to further capitalize on its existing commercial infrastructure and expertise in this specialized therapeutic area.

The details

Pelthos Therapeutics was previously a subsidiary of Ligand Pharmaceuticals before merging with Channel Therapeutics and going public on the NYSE in July 2025. The company raised $50 million in a PIPE financing at the time of the merger. ZELSUVMI, Pelthos' lead product, is a topical nitric oxide-releasing treatment for molluscum contagiosum, a common viral skin infection primarily affecting children. Since launching in July 2025, ZELSUVMI has seen a 129% increase in prescriptions from Q3 to Q4, with net revenue growing from $7.1 million to $9.1 million. Pelthos has also exceeded 4,200 unique prescribers for the product. The company recently acquired the rights to Xepi, a treatment for impetigo, and Xeglyze, a head lice medication, to further expand its pediatric dermatology portfolio. Pelthos plans to launch Xepi in early 2027 and Xeglyze in the second quarter of 2027.

  • On July 1, 2025, Pelthos merged with Channel Therapeutics and began trading on the NYSE.
  • ZELSUVMI was launched on July 10, 2025.
  • Pelthos expects to stand up Xepi manufacturing during 2026 and conduct a full formal launch in early 2027.
  • Pelthos targets a formal launch of Xeglyze in the latter half of Q2 2027.

The players

Scott Plesha

Chief Executive Officer of Pelthos Therapeutics.

Frank Knuettel II

Chief Financial Officer of Pelthos Therapeutics.

Pelthos Therapeutics

A clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain, with a clinical focus on selectively targeting the sodium ion-channel known as 'NaV1.7'.

ZELSUVMI

Pelthos Therapeutics' lead product, a topical nitric oxide-releasing treatment for molluscum contagiosum.

Xepi

A treatment for impetigo that Pelthos recently acquired the rights to.

Xeglyze

A head lice medication that Pelthos recently acquired the rights to.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee

The takeaway

Pelthos Therapeutics is expanding its pediatric dermatology portfolio by adding Xepi and Xeglyze to its successful lead product ZELSUVMI. This strategic move allows the company to leverage its existing commercial infrastructure and expertise to drive growth in specialized treatment areas.